CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 96 enrolled
Drug / intervention
Degarelix +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04397718
NCT04397718Phase 2Completed
CompareCT.gov

Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH): A Multicenter, Phase 2 Randomized Controlled Trial of Best Supportive Care (BSC) vs BSC Plus Degarelix

VA Office of Research and Development·interventional·Posted May 21, 2020·Updated Jun 6, 2022

In Brief

A Phase 2 clinical trial evaluating Degarelix and Saline for COVID-19. Completed, enrolled 96 participants across 14 sites.

Detailed Summary

The purpose of this study is to determine if temporary androgen suppression improves the clinical outcomes of Veterans who are hospitalized to an acute care ward due to COVID-19.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMay 21, 2020
Enrollment StartJul 6, 2020
Primary CompletionJun 8, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.1 years ago

Interventions

Degarelixdrug

Degarelix is an FDA-approved drug for prostate cancer

Salineother

09% Saline